Donaldson Company stock: recent moves and business mix

Donaldson Company (DCI) has been on many investors’ watchlists after a period where the stock has given back some of its earlier gains, with shares down over the past week, month and past 3 months.

At a last close of US$81.94 and a market value of about US$9.7b, the filtration specialist sits at the intersection of several industrial and life sciences end markets, which can matter for how you think about its earnings durability.

Recent trading has been weak, with the stock down over the past week, month and quarter. However, the 1-year total shareholder return of 17.05% and 5-year total shareholder return of 45.92% indicate momentum that has cooled rather than reversed.

If this pullback has you reassessing your watchlist, it could be a good moment to broaden your scope and check out 19 top founder-led companies

With revenue and net income both increasing on an annual basis, and the stock trading about 11% below an estimated intrinsic value and roughly 18% below analyst targets, is this pullback a potential opportunity, or is the market already pricing in future growth?

Most Popular Narrative: 15% Undervalued

With Donaldson Company trading at $81.94 against a narrative fair value of $96.40, the widely followed view is that the stock is pricing in a discount to its modeled long term potential.

Strategic investments and M&A in high-margin, structurally growing segments (e.g., Life Sciences and Food & Beverage filtration) are expected to enhance margin mix and earnings quality, with Life Sciences segment margins improving notably and diversified R&D accelerating product innovation.

Curious what has to happen for that value gap to close? The narrative leans on steadier revenue gains, firmer margins, and a richer earnings profile than today.

The discount rate used in this narrative is 8.46%, which sets the hurdle for those future cash flows and earnings assumptions to justify a fair value around $96.40. Analysts contributing to this view are also baking in measured revenue growth, margin expansion and a future earnings multiple that sits below current sector levels, which together frame the stock as modestly undervalued rather than a high growth outlier.

Result: Fair Value of $96.40 (UNDERVALUED)

However, there are clear watchpoints, including potential pressure on high margin Life Sciences bioprocessing and exposure to any slowdown or policy shocks in China and the broader APAC region.

Another lens on valuation

While the narrative model points to a fair value of US$96.40, the P/E picture is more cautious. Donaldson trades at 25.1x earnings versus a fair ratio of 24.4x, slightly above where the market could gravitate, even though it sits below peer and Machinery industry averages of 30.1x and 26.3x. That mix of mild premium to fair ratio but discount to peers raises a simple question for you: is the risk that the multiple compresses toward the fair ratio, or that it drifts closer to peers instead?

Next Steps

With all this in mind, are sentiment and valuation lining up the way you think, or telling two different stories? Take a closer look at the positives the market is focused on with 3 key rewards

Looking for more investment ideas?

If you stop with just one stock, you could miss opportunities that fit your goals better, so put a few more quality ideas on your radar today.

• Target reliable income streams by scanning companies in the 12 dividend fortresses and see which yields line up with your risk tolerance.
• Hunt for quality at a discount with the screener containing 22 high quality undiscovered gems and spot stocks the market may not be paying full attention to yet.
• Prioritize resilience by reviewing companies in the 66 resilient stocks with low risk scores and focus on businesses with steadier risk profiles.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.